PDCD1 and nasopharyngeal carcinoma: Some trials have shown that the objective efficacy rate of tislelizumab in the treatment of patients with recurrent metastatic NPC is 43%, which is higher than that of other anti-PD-1 monoclonal antibodies.[8] Thus, tislelizumab is a highly promising new treatment for patients with LA-NPC.